SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Jamie Thomas discussing results from the MAST trial assessing the validation of PAM50 for predicting progression in ...
Investigators found that some patients with high-risk nonmetastatic hormone-sensitive prostate cancer were understaged by ...
Researchers at the Garvan Institute of Medical Research have uncovered how pancreatic cancer hijacks a crucial metabolic ...
Prostate cancer remains one of the most commonly diagnosed cancersworldwide, with 1.4 million new cases and over 375,000 ...
A cohort study of over 40,000 patients suggests that levels should be monitored for at least three months — longer than commonly practiced ...
Lu rhPSMA-10.1 showed high tumor radiation with low healthy tissue exposure in a phase 1/2 trial for metastatic ...
Metastatic prostate cancer patients in the Capital Region now have a new treatment option at Ochsner MD Anderson Cancer ...
SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Arjun Pon Avudaiappan discussing survival outcomes of radical prostatectomy versus dose-escalated radiation with ADT ...
Dr. Chandler Park sat down for an interview with CURE® to discuss the biggest takeaway from the 2025 ASCO GU Symposium in ...
An expert discusses alternative treatment options for a symptomatic patient with metastatic castration-resistant prostate ...
Prostate cancer was the second leading cause of cancer deaths in North Carolina men in 2021; the bill aims to lower those rates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback